Nautilus Biotechnology, Inc. (NAUT) Stock: Financials, SEC Filings & Ownership
Market cap: $412.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 412.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 27 Oct, in 3 days
Price
The price chart — with earnings days, unusual moves, 8-Ks and insider trades marked — opens with a free account.
Our verdict
Five questions and why →Our read on this company
The verdict, the score behind it and the written thesis are in Analyst.
Try it free for 7 daysTiming
Today's price conditions
The verdict, the score behind it and the written thesis are in Analyst.
Try it free for 7 daysAnalyst note
Our written read on this company
The verdict, the score behind it and the written thesis are in Analyst.
Try it free for 7 daysDividends & buybacks
yield — · payout —No dividends or buybacks in the filed statements.
Performance
price return · vs. S&P 500 and the sector| Window | NAUT | vs. S&P 500 | vs. sector |
|---|---|---|---|
| 1 month | +227.1% | — | — |
| 3 months | +95.2% | — | — |
| 6 months | +23.7% | — | — |
| Year to date | +69.6% | — | — |
| 1 year | +157.1% | — | — |
Nautilus Biotechnology, Inc. — questions
- What does Nautilus Biotechnology, Inc. do?
- Nautilus Biotechnology, Inc. is a scientific & technical instruments company in the technology sector. In its SEC filings it reports 2 business lines: Grant revenue (95%), Service revenue (5%).
- What is Nautilus Biotechnology, Inc.'s market cap?
- $412.3M.
- When does Nautilus Biotechnology, Inc. report earnings?
- Nautilus Biotechnology, Inc.'s next earnings report is expected on 2026-10-27.
Every figure on this page comes from Nautilus Biotechnology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.